0.56

1.63% +0.009

Kineta Inc (KA)

Overview News Price History Financials Discussions Forecast

Kineta Inc stock is currently priced at $0.56, with a 24-hour trading volume of 51,678. It has seen a +1.63% increased in the last 24 hours and a +13.48% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.573 pivot point. If it approaches the $0.529 support level, significant changes may occur.

Previous Close:

$0.551

Open:

$0.551

24h Volume:

51,678

Market Cap:

$5.82M

Revenue:

$5.22M

Net Income/Loss:

$-14.10M

P/E Ratio:

-0.1848

EPS:

-3.03

Net Cash Flow:

$-16.21M

1W Performance:

-12.47%

1M Performance:

+13.48%

6M Performance:

-87.24%

1Y Performance:

-86.37%

1D Range:

$0.5001

$0.5785

52W Range:

$0.3339

$5.39

Kineta Inc Stock (KA) Company Profile

Name

Kineta Inc

Sector

Healthcare (1193)

Industry

Biotechnology (685)

Phone

206 378 0400

Address

219 Terry Ave. N, Suite 300, Seattle

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

KA's Discussions on Twitter

Kineta Inc Stock (KA) Latest News

Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

GlobeNewswire Inc.

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire Inc.

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Kineta Inc Stock (KA) Financials Data

Kineta Inc (KA) Revenue 2024

KA reported a revenue (TTM) of $5.22 million for the quarter ending June 30, 2023.

Kineta Inc (KA) Net Income 2024

KA net income (TTM) was -$14.10 million for the quarter ending December 31, 2023, a +77.76% increase year-over-year.

Kineta Inc (KA) Cash Flow 2024

KA recorded a free cash flow (TTM) of -$16.21 million for the quarter ending December 31, 2023, a +15.14% increase year-over-year.

Kineta Inc (KA) Earnings per Share 2024

KA earnings per share (TTM) was -$1.38 for the quarter ending December 31, 2023, a +89.29% growth year-over-year.

Kineta Inc Stock (KA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Bartoszek Raymond J.	Director	Dec 05 '23	Buy	4.50	1,000	4,500	16,956
Bartoszek Raymond J.	Director	Dec 04 '23	Buy	4.33	1,000	4,325	15,956
Iadonato Shawn	Chief Executive Officer	Nov 29 '23	Buy	3.51	4,100	14,403	675,230
PHILIPS CRAIG W.	President	Nov 28 '23	Buy	3.27	3,000	9,812	60,811
Iadonato Shawn	Chief Executive Officer	Nov 28 '23	Buy	3.33	900	2,995	671,130
Foote Marion R	Director	Oct 11 '23	Option Exercise	0.14	4,443	622	143,204
PHILIPS CRAIG W.	President	Sep 21 '23	Buy	2.40	2,900	6,970	57,811
Iadonato Shawn	Chief Executive Officer	Sep 20 '23	Buy	2.50	10,000	25,042	670,230
Kenny Pauline	General Counsel & Secretary	Sep 20 '23	Buy	2.58	1,500	3,870	18,448
PHILIPS CRAIG W.	President	Sep 20 '23	Buy	2.54	600	1,525	54,911

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.